Welcome to our dedicated page for Hologic news (Ticker: HOLX), a resource for investors and traders seeking the latest updates and insights on Hologic stock.
Hologic Inc. (NASDAQ: HOLX) is a leading global healthcare company dedicated to the science of sure. Headquartered in Bedford, Massachusetts, Hologic specializes in developing, marketing, and servicing some of the most innovative and accurate diagnostic imaging systems and surgical products available today. The company's core business focuses on meeting the healthcare needs of women, operating through five primary segments: diagnostics, breast health, surgical, and skeletal health.
Diagnostics, which accounts for 60% of total sales, has seen a significant boost due to the pandemic, underscoring the company's strategic pivot toward commercial diagnostics following the acquisition of Gen-Probe. This segment includes a wide range of tests and instruments essential for early disease detection and management.
Breast Health, traditionally a cornerstone of Hologic’s business, contributes 14% to total sales. Though this segment was initially suppressed by the pandemic, it remains vital for innovations in mammography and breast surgery. Hologic's Surgical segment, representing 11% of sales, offers advanced products that enhance surgical outcomes and patient safety. The Skeletal Health segment, although smaller at 1% of total sales, provides critical tools for assessing bone health.
Hologic’s reach is vast, with the United States accounting for 69% of its revenue, followed by Europe at 20%, Asia at 8%, and other international markets making up the remaining 3%. The company's diverse, dedicated, and creative team is committed to not only advancing medical science but also providing greater confidence and peace of mind in diagnosis, enabling healthier lives worldwide.
Stay updated with the latest from Hologic by connecting on Hologic.com, Facebook, and Twitter.
Hologic, Inc. (NASDAQ: HOLX), a leader in women’s health, announces its sponsorship of Mary J. Blige’s “Good Morning Gorgeous” tour from September 17 to October 29, 2022. The initiative aims to promote preventive care and Well Woman Exams. The partnership includes a sweepstakes for fans to win concert tickets and a public service announcement featuring Blige. Hologic emphasizes the importance of screenings, particularly for underserved communities, showcasing its commitment to women's health.
Hologic, Inc. (NASDAQ: HOLX) received a favorable ruling from the U.S. Court of Appeals for the Federal Circuit, which upheld a 2018 district court decision blocking Minerva from disputing the validity of patents assigned to Hologic. This ruling, relating to a lawsuit filed in 2015 over alleged patent infringement by Minerva’s endometrial ablation system, requires Minerva to pay Hologic over $7 million in damages. Hologic's acquisition of Novacept's patents in 2004 has been confirmed, fostering confidence for companies acquiring innovative technologies in the medical field.
Active Motif has licensed its foundational patents in transposition for CUT&Tag epigenetic assays to Diagenode S.A., a Hologic company (NASDAQ: HOLX). This licensing agreement aims to enhance the understanding of biological processes through improved access to patented technologies, including US9938524 and others. The Cut&Tag-IT technology will aid mechanistic, translational, and clinical research. Active Motif focuses on developing tools for nuclear function analysis, serving a global customer base in scientific and pharmaceutical fields.
Hologic, Inc. reported third-quarter revenue of $1.003 billion, with GAAP diluted EPS of $0.90 and non-GAAP diluted EPS of $0.95, exceeding expectations. Global organic molecular diagnostics revenue grew over 20% in constant currency, while overall revenue declined 14.2% year-over-year, mainly due to lower COVID-19 assay sales and semiconductor supply chain issues. The company has raised its full-year revenue and EPS guidance, reflecting confidence in its diagnostics and surgical business.
Hologic, Inc. (NASDAQ: HOLX) is set to showcase its innovative breast and skeletal health solutions at the European Congress of Radiology in Vienna from July 13-17. The company aims to address challenges in early detection caused by pandemic delays. Attendees can explore Hologic's 3D Mammography™ technology and participate in scientific talks at the Scientific Innovation Hub. Highlights from the inaugural Hologic Global Women’s Health Index will also be shared, focusing on women's health perspectives. This event underscores Hologic's commitment to improving women's health.
Hologic, Inc. (Nasdaq: HOLX) has launched its Panther Fusion® SARS-CoV-2/Flu A/B/RSV assay and Novodiag® RESP-4 assay in the European Union, enhancing its molecular diagnostics offerings for the upcoming respiratory viral season. These assays identify four prevalent respiratory viruses, using nasopharyngeal swab samples. The products comply with EU regulations and aim to improve patient care by allowing healthcare providers to differentiate between similar viral infections. This marks a significant expansion in Hologic's diagnostic capabilities following the acquisition of Mobidiag.
Hologic, Inc. (NASDAQ: HOLX) will release its third quarter fiscal 2022 financial results on July 27, after market close. A conference call is scheduled for 4:30 p.m. ET that day. Interested parties can join by calling 800-289-0720 in the U.S. or +1-323-701-0160 internationally, using access code 6025981. The call will also be available via a live webcast on the company's investor website, and an archived replay will be provided after the call for 30 days.
Hologic, Inc. (Nasdaq: HOLX) has received CE marking for its new Panther Fusion EBV and BKV Quant Assays, expanding its transplant pathogen monitoring capabilities. These in vitro nucleic acid amplification tests enable accurate quantitation of Epstein-Barr Virus and BK Virus in transplant patients, crucial for diagnosis and treatment management. The Panther Fusion system processes whole blood and plasma samples, which are vital for monitoring viral levels. This marks a significant addition as the first quantitative assays from Hologic's Liege facility.
FAQ
What is the current stock price of Hologic (HOLX)?
What is the market cap of Hologic (HOLX)?
What does Hologic Inc. specialize in?
Where is Hologic Inc. headquartered?
What are the main segments of Hologic’s business?
Which segment contributes the most to Hologic's revenue?
How has the pandemic affected Hologic’s business segments?
What percentage of Hologic’s revenue comes from the United States?
How did the acquisition of Gen-Probe impact Hologic?
How can I stay updated with Hologic's latest news?
What is Hologic’s approach to healthcare?
What percentage of Hologic’s revenue comes from international markets?
